Schedule III momentum and expanded research could accelerate cannabis growth in 2026—pushing brands to scale, standardize quality, and stay compliance‑ready.

Schedule III Cannabis: Understanding the Focus, Scope, and Industry Impact The December 18, 2025 White House executive order directing the Attorney General to complete marijuana rescheduling to Schedule III represents a fundamental shift in federal cannabis policy. The core focus of Schedule III classification centers on formal federal recognition that cannabis possesses currently accepted medical […]

